This little boy from Cuba got the first approved gene therapy for skin disease

[ad_1]

Herpes virus

Scientists now have numerous tools to manipulate genes in their labs, where fixing cells in a dish or even curing mice of deadly conditions is commonplace. But the challenge in treating people is that it is harder to get corrected DNA into their bodies, a problem known as gene delivery.

Krystal is among dozens of companies seeking innovative ways to deliver replacement genes to more locations in the human body, including hard-to-reach organs like the brain.

“Delivery is the most important factor in genetic medicine,” says Maxx Chatsko, founder of Solt DB, a publisher and investment analysis company, who also buys and sells shares in biotech companies (including Krystal). “I think this could eventually be the first gene therapy people dose at home.”

Gene delivery usually involves placing a DNA strand inside a virus naturally equipped to enter a human cell and drop off the gene. In Krystal’s case, the company is using herpes simplex virus, the same one that causes cold sores.

HSV-1, as the virus is known, is very common—about half the people in the world are infected by it. That means it is fairly safe, but it also has the advantage that it naturally evades the immune system. Krishnan says that feature is what permits the drug to be used repeatedly, without causing negative reactions.

While the startup has been successful, Chatsko says there has also been some controversial over how it hit upon its strategy. In 2022, Krystal agreed to pay up to $75 million to another startup, PeriphaGen, which accused Krishnan and the company of pilfering its ideas and technology.

Eye drops

WHETHER or Not This is a Case of a Stolen “Eureka,” Krystal Has Already DemonStrated the Versaticity of its Approach by Development An Eye Version of the DRUG A. THEEEST of Anthony’s Ophthalmology, Alfonso Sabater, Director of the Corneal Innovation Lab AT The University of Miami’s medical school.

“When I learned he was in the skin trial, I thought, why don’t we try that on the eye,” says Sabater, who reached a special agreement with the FDA to test the idea on a single patient, Anthony. First, Sabater surgically removed a layer of scar tissue that had built up on Anthony’s eyes. After that, he says, monthly use of the eye drops appears to have stopped those injuries from returning.

[ad_2]

Source link

Recommended For You

About the Author: News Center